The findings suggest that use of the pacing technique during CRT should be reserved for expert operators, at least for now.
Medtronic and Biotronik both took steps forward this week with their pacemaker hardware designed to target newly emerging ...
A 173-patient randomized trial in HFrEF (LVEF ≤35%) with LBBB (QRS ≥130 ms) showed CSP was inferior to BiVP for a hierarchical 12‑month composite endpoint. Worse outcomes with CSP were reflected by an ...
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, received U.S. Food and Drug Administration (FDA) approval for an expanded indication for the OmniaSecure™ defibrillation lead. Now ...
Two multicenter trials drew different conclusions about the value of conduction system relative to biventricular pacing for ...
Medtronic (NYSE: MDT) announced today that it received FDA approval for an expanded indication for its OmniaSecure defibrillation lead.
Built for high reliability, world's only lumenless defibrillation lead approved for placement in the left bundle branch area GALWAY, Ireland, March 23, 2026 /PRNewswire/ -- Medtronic plc ...
Lucknow: King George's Medical University (KGMU) has introduced ‘Advanced Conduction System Pacing', a new pacemaker method, which helps the heart bea.
Medical societies are urging the adoption of ALARA+, the new cath lab standard of "as low and as light as reasonably ...
Cardiac resynchronization therapy is a key treatment for patients with HFrEF and electrical dyssynchrony, such as LBBB. While ...
Medical Device Network on MSN
Medtronic’s OmniaSecure defib lead nets another FDA approval
OmniaSecure is now the first defibrillation lead approved for placement in the left bundle branch.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results